Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company’s portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release ca...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $770.0K
Senior Vice President of Product Development
Total Annual Compensation: $503.0K
Chief Medical Officer
Total Annual Compensation: $313.9K
Compensation as of Fiscal Year 2015.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 08:00 AM
Jun 28 16
Adamas Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 08:00 AM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Gregory T. Went, Chairman and Chief Executive Officer.
Adamas Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Proof-Of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
Jun 13 16
Adamas Pharmaceuticals, Inc. announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) extended-release capsules in individuals with multiple sclerosis (MS) who have impaired walking. Data from the study suggest that ADS-5102 is well tolerated in the MS patient population and has a significant positive impact on walking speed. The company plans to present these data at an upcoming scientific conference. The Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study evaluated ADS-5102 dosed at 340 mg once daily in an MS population for four weeks. Efficacy analyses were based on a modified intent-to-treat population (n=56). A key walking assessment was the timed 25-foot walk (T25FW) test, a well-established outcome measure. The T25FW test has previously been used as a basis for product approval in the United States and Europe. An approximately 15 percent placebo-adjusted improvement in walking speed was seen in the T25FW (p<0.05). The other walking performance measures used in this trial were directionally consistent. Further analyses are underway related to fatigue, depression and cognition. The types of adverse events (AEs) reported with ADS-5102 in this study were consistent with the known safety profile of amantadine. The majority of study participants experienced at least one AE (17 patients in the ADS-5102 group and 19 patients in the placebo group). Of these patients, the recorded AE intensity was mild or moderate in the majority of patients (88 percent in the ADS-5102 group; 100% in the placebo group). Five patients discontinued study drug due to an AE; all of these patients were in the ADS-5102 group. Of these patients, one patient experienced a serious AE, which was deemed study drug related in the context of a multi-factorial clinical presentation.
Adamas Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016
May 10 16
Adamas Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2016. For the quarter, the company announced revenue of $175,000 compared to $226,000 for the same period a year ago. Loss from operations was $13,988,000 compared to $12,226,000 for the same period a year ago. Loss before income taxes was $13,828,000 compared to $12,148,000 for the same period a year ago. Net loss was $13,828,000 compared to $12,202,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.65 compared to $0.69 for the same period a year ago. Net cash used in operating activities was $12,502,000 compared to $14,065,000 for the same period a year ago. Purchases of property and equipment was $461,000 compared to $18,000 for the same period a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|